The meningococcal conjugate vaccine or MCV4 was approved in 2005. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body's immune cells.

The Advisory Committee on Immunization Practices has updated its recommendations for the revaccination of persons at prolonged increased risk for meningococcal disease.

Meningococcal Vaccine. The meningococcal vaccine (MCV4) protects against some types of meningitis. Two doses are currently recommended to decrease the risk of disease with the first vaccination ...

In January 2005, the U.S. Food and Drug Administration licensed a new tetravalent meningococcal conjugate vaccine ([MCV4] Menactra) for use in people 11-55 years of age.

The quadrivalent meningococcal conjugate vaccine appeared safe for use and effective at preventing disease in adolescents with HIV, although response rates still remained lower than in healthy ...

Meningococcal conjugate vaccines (MenACWY or MCV4). One of these vaccines, Menveo, is approved for anyone aged 2 months to 55 years, while the other, MenQuadfi, is used for those aged 2 years or ...

The bivalent rLP2086 meningococcal serogroup B vaccine coadministered with MCV4 and Tdap met noninferiority immunogenicity criteria without a clinically significant increase in reactogenicity, a ...

In adolescents aged 11 to 14 years, must the human papillomavirus; meningococcal (MCV4); tetanus, diphtheria, and pertussis (Tdap); and, if needed, varicella vaccines be given simultaneously?

Children aged 2 to 10 years with HIV responded well with few adverse events to the quadrivalent meningococcal vaccine, according to study results. The trial was conducted because children with HIV ...